Preclinical mRNA-LNP platform developing antigen-specific immune tolerance therapies for patients with T-cell–driven autoimmune diseases, with demonstrated reversal of Type 1 diabetes in animal models. Platform co-delivers multiple mRNA-encoded antigens/epitopes and small-molecule immune modulators within lipid nanoparticles to induce antigen-specific tolerance and improve therapeutic safety/effectiveness.